Welcome to our dedicated page for Astera Labs SEC filings (Ticker: ALAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Astera Labs's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time SEC filing updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Astera Labs's regulatory disclosures and financial reporting.
ALAB shareholder Stefan A. Dyckerhoff filed a notice to sell common stock through broker Stifel Nicolaus & Company Inc. The planned sale covers 12,499 shares of common stock with an aggregate market value of $3,897,584.00. The filing cites approximately 171,410,000 shares outstanding as of August 6, 2026. The shares were originally acquired via pro-rata distributions from Sutter Hill Ventures A CA LP and through private placements with the issuer. The filing also lists past sales of 12,499 shares on June 3, 2026 for $4,553,995.00 and 12,499 shares on July 1, 2026 for $5,624,555.00.
Astera Labs, a semiconductor company focused on cloud and AI connectivity, reported rapid year-over-year growth in Q2 2026. Revenue was $392.4 million, up 104% from Q2 2025, and first-half revenue reached $700.8 million, up 99%. GAAP gross margin remained high at 73.3%, though down 250 basis points from a year earlier due to a greater mix of lower-margin hardware modules and warrant-related revenue reductions.
Operating income rose to $89.2 million in Q2 and $151.1 million for the first half, while net income increased to $153.1 million in Q2 and $233.4 million year-to-date, supported by a $50.3 million Q2 income tax benefit tied to equity compensation and tax credits. Cash, cash equivalents, and marketable securities totaled $1.3 billion, with $162.3 million of operating cash flow in the first half. The company completed a $74.0 million technology acquisition adding $68.4 million of goodwill and continues to invest heavily in R&D and headcount, while revenue remains concentrated in China, Singapore and Taiwan and among a small number of large customers.
Astera Labs, Inc. reported record preliminary results for the quarter ended June 30, 2026, with revenue of $392.4 million, up 27% sequentially and 104% year-over-year. GAAP gross margin was 73.3%, GAAP operating income was $89.2 million with a 22.7% margin, and GAAP net income reached $153.1 million, or $0.83 per diluted share. On a non-GAAP basis, operating income was $153.5 million with a 39.1% margin, non-GAAP net income was $145.8 million, and non-GAAP diluted EPS was $0.80.
Total assets were $1.93 billion as of June 30, 2026, including $111.5 million of cash and cash equivalents and $1.14 billion of marketable securities, with stockholders’ equity of $1.73 billion. For the first six months of 2026, the company generated $162.3 million of cash from operating activities. For the third quarter of 2026, Astera Labs guides revenue between $540 million and $560 million, GAAP gross margin of approximately 72%, GAAP diluted EPS of $0.87 to $0.92, and non-GAAP diluted EPS of $1.16 to $1.21, supported by ramping Scorpio fabric switches and an expanded AI connectivity portfolio.
BlackRock, Inc. reports beneficial ownership of 12,667,232 shares of Astera Labs Inc. common stock, representing 7.4% of the outstanding class as of June 30, 2026. BlackRock has sole voting power over 11,998,990 shares and sole dispositive power over all 12,667,232 shares.
The position is held across certain reporting business units of BlackRock and its subsidiaries. Various underlying clients have rights to dividends and sale proceeds, but no single client has more than 5% of Astera Labs’ total outstanding common shares.
Cota Germaine reported acquisition or exercise transactions in this Form 4 filing.
Astera Labs, Inc. granted Chief Accounting Officer and VP, Finance Germaine Cota an award of 1,451 restricted stock units of common stock on July 20, 2026 under its 2024 Stock Option and Incentive Plan. Following this award, Cota directly holds 26,440 shares of common stock.
The award provides that 6.25% of the RSUs shall vest in 16 equal quarterly installments after the vesting commencement date of August 15, 2026, conditioned on a continuous service relationship with the company. Each RSU represents a contingent right to receive one share of common stock.
Astera Labs director Manuel Alba reported pre-planned insider sales tied to an affiliated entity. On July 1, 2026, Casa Alameda 2007, LLC, of which Alba is a manager, sold 8,491 shares of Astera Labs common stock in multiple open-market transactions under a Rule 10b5-1 trading plan adopted on May 29, 2025.
The Form 4 notes weighted average sale prices, with individual trades executed in ranges from $451.4600 to $468.0000 per share. After these transactions, Casa Alameda 2007, LLC held 286,863 shares indirectly, while Alba also reported 2,351 shares held directly and 5,000 shares held indirectly by his spouse. Alba disclaims beneficial ownership of the LLC-held shares except to the extent of any pecuniary interest.
Astera Labs, Inc. director Manuel Alba reported a series of automatic, pre-planned stock sales linked to entities associated with him. On July 1, 2026, Casa Alameda 2007, LLC and the Alba 2003 Living Trust together sold 37,535 shares of Astera Labs common stock in 29 open-market transactions.
The filing states these sales occurred automatically under a Rule 10b5-1 trading plan adopted on May 29, 2025. Alba disclaims beneficial ownership of the securities held by Casa Alameda 2007, LLC and by the Alba Trust, except to the extent of any pecuniary interest.
Astera Labs director-related trust reports pre-planned stock sales. Alba 2003 Living Trust, associated with director Manuel Alba, sold a total of 136,974 shares of Astera Labs common stock on July 1, 2026 in multiple open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The reported sale prices ranged from $429.11 to $459.44 per share, based on weighted-average pricing disclosures. Following these transactions, the trust continues to hold 1,287,524 shares of Astera Labs common stock indirectly for the benefit of the Alba 2003 Living Trust, with Manuel Alba-Marquez and his spouse as co-trustees, and Manuel Alba disclaiming beneficial ownership except to the extent of any pecuniary interest.
Astera Labs, Inc. director Stefan A. Dyckerhoff reported planned stock sales through various entities. On 2026-07-01, entities associated with him sold a total of 12,499 shares of Astera Labs common stock at $450.00 per share in open-market transactions under a pre-arranged Rule 10b5-1 trading plan.
The sales included 3,505 shares from his direct holdings, 8,333 shares held by a trust, and 661 shares held by a limited partnership. After these transactions, reported positions include 57,466 shares held directly, 311,399 shares held by a trust, 4,631 shares held by a limited partnership, and several smaller indirect holdings, with Dyckerhoff disclaiming beneficial ownership except for his pecuniary interests.
Morgan Stanley Smith Barney LLC submitted a Form 144 reporting an intended sale of 170,000 shares of Common Stock of ALAB. The filing lists an associated figure of $82,113,400.00 and shows 171,407,939 shares outstanding as of 07/01/2026. The securities were acquired 03/21/2018 in a Private Acquisition from Issuer or an Affiliate for Cash.